ATMUS FILTRATION TECHNOLOGIES INC.
Atmus Filtration Technologies Inc (ATMU) develops inhalation and nasal drug‑delivery systems alongside filtration and device engineering services for pharmaceutical partners. The company aims to commercialise integrated device‑and‑drug solutions that can improve therapy delivery for respiratory and nasal conditions, leveraging specialised know‑how in aerosol and filtration technology. Key investor considerations include revenue potential from licensing and partner programmes, the need for regulatory approvals for device‑drug combinations, and the practical challenges of scaling manufacturing. With a market capitalisation of about $3.67bn, Atmus sits in a specialised part of the healthcare‑equipment market where collaborations and intellectual property matter. Risks include regulatory setbacks, competition from larger device makers, and variable adoption by pharma customers. This summary is general, educational information and not personal investment advice; values can rise or fall and past performance is not a reliable indicator of future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ATMUS Filtration Technologies' stock, with a target price suggesting potential growth.
Financial Health
Atmus Filtration Technologies is performing well, with strong sales and cash generation.
Dividend
ATMUS Filtration Technologies' low dividend yield of 0.4% indicates limited returns for investors seeking dividends. If you invested $1000 you would be paid $4 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ATMU
The North Ablaze: Investing In Wildfire Resilience
This carefully selected group of stocks offers exposure to companies tackling Canada's unprecedented wildfire crisis. Our professional analysts have identified businesses positioned to benefit from increased spending on wildfire suppression, air quality solutions, and carbon monitoring technologies.
Published: July 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth via Partnerships
Atmus’s collaborations with pharmaceutical companies can scale revenue through licensed device‑drug pairings, though outcomes depend on regulatory success and commercial adoption.
Technology Edge
Proprietary inhalation and filtration technologies may differentiate offerings and attract deals, but R&D and regulatory risk mean results are uncertain.
Demand Drivers
Global respiratory disease trends and ageing populations support long‑term demand for delivery devices, although competition and reimbursement pressures remain considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
